LONDON: The University of Cambridge is aiming to start clinical trials of its possible COVID-19 vaccine in the autumn after it received £1.9 million (US$2.5 million) in funding from the British government, the university said on Wednesday (Aug 26).
The scientists behind the vaccine said their approach, which uses genetic sequences of all known coronaviruses to hone the immune response, could help avoid the adverse effects of a hyper-inflammatory immune response.
Advertisement
Advertisement
READ: WHO says 172 countries engaging with global COVID-19 vaccine plan
READ: Trump administration moves to advance COVID-19 treatment, possible vaccine: Reports
"We're looking for chinks in its armour, crucial pieces of the virus that we can use to construct the vaccine to direct the immune response in the right direction," Jonathan Heeney, head of the Laboratory of Viral Zoonotics at the University of Cambridge, said.
"Ultimately we aim to make a vaccine that will not only protect from SARS-CoV-2, but also other related coronaviruses that may spill over from animals to humans."
Advertisement
Advertisement
No vaccine against the SARS-CoV-2 coronavirus which causes COVID-19 has yet been proven clinically effective, though 30 that use a range of technologies are in human trials already.
READ: Oxford coronavirus vaccine data could go to regulators this year
The Cambridge candidate, DIOS-CoVax2, is DNA based. Computer-generated antigen structures are encoded by synthetic genes, which can then re-programme the body's immune system to produce antibodies against the coronavirus.
This DNA vector method has been shown to be safe and effective at stimulating an immune response in other pathogens in early-stage trials, the university said.
Although it is operating at a later timetable than some other vaccine candiRead More – Source
[contf] [contfnew] 
channel news asia
[contfnewc] [contfnewc]
